24 May 2013
Keywords: emselex, shows, good, safety, profile, new, data
Article | 06 September 2004
New data shows that Novartis' Emselex (Enablex; darifenacinhydrobromide) has better tolerability and equal efficacy to oxybutynin
in the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 September 2004
23 May 2013
© 2013 thepharmaletter.com